SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(FitzGerald Oliver) "

Sökning: WFRF:(FitzGerald Oliver)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Gossec, L., et al. (författare)
  • European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update
  • 2016
  • Ingår i: Annals of the Rheumatic Diseases. - London : BMJ Books. - 0003-4967 .- 1468-2060. ; 75:3, s. 499-510
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations.METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated.RESULTS: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used.CONCLUSIONS: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion. © 2015 BMJ Publishing Group Ltd & European League Against Rheumatism.
  •  
2.
  • Apel, Maria, et al. (författare)
  • Variants in RUNX3 Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis
  • 2013
  • Ingår i: Arthritis and Rheumatism. - 0004-3591 .- 1529-0131. ; 65:5, s. 1224-1231
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective Psoriatic arthritis (PsA) is a common inflammatory joint disease distinct from other chronic arthritides and frequently accompanied by psoriasis vulgaris. In a first genome-wide association study (GWAS), we were able to identify several genetic risk factors. However, even combined with previously identified factors, the genetic contribution to disease was not fully explained. Therefore, we undertook this study to investigate further 17 loci from our GWAS that did not reach genome-wide significance levels of association in the initial analysis. Methods Twenty-one of 22 single-nucleotide polymorphisms were successfully genotyped in independent cohorts of 1,398 PsA patients and 6,389 controls and in a group of 964 German patients with psoriasis vulgaris. Results Association with a RUNX3 variant, rs4649038, was replicated in independent patients and controls and resulted in a combined P value of 1.40 x 108 by Cochran-Mantel-Haenszel test and an odds ratio (OR) of 1.24 (95% confidence interval [95% CI] 1.151.33). Further analyses based on linkage disequilibrium (LD) at RUNX3 refined the most significant association to an LD block located in the first intron of one isoform. Weaker evidence for association was detected in German patients with psoriasis vulgaris (P = 5.89 x 102; OR 1.13 [95% CI 1.001.28]), indicating a role in the skin manifestations of psoriasis. Conclusion Our analyses identified variants in RUNX3 as susceptibility factors for PsA. RUNX3 has already been implicated in susceptibility to ankylosing spondylitis, another spondyloarthritis, although its risk allele is independent from the one for PsA. RUNX-3 is involved in CD8+ T lymphocyte differentiation and is therefore a good candidate for involvement in PsA and psoriasis vulgaris as T cellmediated diseases.
  •  
3.
  • Cobb, Joanna E., et al. (författare)
  • Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans
  • 2013
  • Ingår i: PLoS ONE. - : Public Library of Science, PLOS. - 1932-6203 .- 1932-6203. ; 8:6, s. e66456-
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: Genome-wide association studies have facilitated the identification of over 30 susceptibility loci for rheumatoid arthritis (RA). However, evidence for a number of potential susceptibility genes have not so far reached genome-wide significance in studies of Caucasian RA.Methods: A cohort of 4286 RA patients from across Europe and 5642 population matched controls were genotyped for 25 SNPs, then combined in a meta-analysis with previously published data.Results: Significant evidence of association was detected for nine SNPs within the European samples. When meta-analysed with previously published data, 21 SNPs were associated with RA susceptibility. Although SNPs in the PTPN2 gene were previously reported to be associated with RA in both Japanese and European populations, we show genome-wide evidence for a different SNP within this gene associated with RA susceptibility in an independent European population (rs7234029, P = 4.4x10(-9)).Conclusions: This study provides further genome-wide evidence for the association of the PTPN2 locus (encoding the T cell protein tyrosine phosphastase) with Caucasian RA susceptibility. This finding adds to the growing evidence for PTPN2 being a pan-autoimmune susceptibility gene.
  •  
4.
  • Craddock, Nick, et al. (författare)
  • Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls
  • 2010
  • Ingår i: Nature. - 0028-0836 .- 1476-4687. ; 464:7289, s. 713-720
  • Tidskriftsartikel (refereegranskat)abstract
    • Copy number variants (CNVs) account for a major proportion of human genetic polymorphism and have been predicted to have an important role in genetic susceptibility to common disease. To address this we undertook a large, direct genome-wide study of association between CNVs and eight common human diseases. Using a purpose-designed array we typed,19,000 individuals into distinct copy-number classes at 3,432 polymorphic CNVs, including an estimated similar to 50% of all common CNVs larger than 500 base pairs. We identified several biological artefacts that lead to false-positive associations, including systematic CNV differences between DNAs derived from blood and cell lines. Association testing and follow-up replication analyses confirmed three loci where CNVs were associated with disease-IRGM for Crohn's disease, HLA for Crohn's disease, rheumatoid arthritis and type 1 diabetes, and TSPAN8 for type 2 diabetes-although in each case the locus had previously been identified in single nucleotide polymorphism (SNP)-based studies, reflecting our observation that most common CNVs that are well-typed on our array are well tagged by SNPs and so have been indirectly explored through SNP studies. We conclude that common CNVs that can be typed on existing platforms are unlikely to contribute greatly to the genetic basis of common human diseases.
  •  
5.
  • Hüffmeier, Ulrike, et al. (författare)
  • Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis
  • 2010
  • Ingår i: Nature Genetics. - 1061-4036 .- 1546-1718. ; 42:11, s. 996-999
  • Tidskriftsartikel (refereegranskat)abstract
    • Psoriatic arthritis (PsA) is an inflammatory joint disease that is distinct from other chronic arthritides and which is frequently accompanied by psoriasis vulgaris (PsV) and seronegativity for rheumatoid factor. We conducted a genome-wide association study in 609 German individuals with PsA (cases) and 990 controls with replication in 6 European cohorts including a total of 5,488 individuals. We replicated PsA associations at HLA-C and IL12B and identified a new association at TRAF3IP2 (rs13190932, P = 8.56 × 10⁻¹⁷). TRAF3IP2 was also associated with PsV in a German cohort including 2,040 individuals (rs13190932, P = 1.95 × 10⁻³). Sequencing of the exons of TRAF3IP2 identified a coding variant (p.Asp10Asn, rs33980500) as the most significantly associated SNP (P = 1.13 × 10⁻²⁰, odds ratio = 1.95). Functional assays showed reduced binding of this TRAF3IP2 variant to TRAF6, suggesting altered modulation of immunoregulatory signals through altered TRAF interactions as a new and shared pathway for PsA and PsV.
  •  
6.
  •  
7.
  • Tidskriftsartikel (refereegranskat)
  •  
8.
  • Tidskriftsartikel (refereegranskat)
  •  
9.
  • Tidskriftsartikel (refereegranskat)
  •  
10.
  • Tidskriftsartikel (refereegranskat)
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (235)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (237)
Författare/redaktör
Aad, G (281)
Zwalinski, L. (246)
Abdinov, O (223)
Bocchetta, Simona (223)
BRYNGEMARK, LENE (223)
Lytken, Else (223)
visa fler...
Zhang, Z. (223)
Maddocks, H. J. (223)
Kastanas, A. (223)
Ohm, C. C. (223)
Annovi, A. (223)
Artamonov, A. (223)
Abolins, M. (223)
Abreu, H. (223)
Adye, T. (223)
Akimov, A. V. (223)
Albrand, S. (223)
Aleksa, M. (223)
Aleksandrov, I. N. (223)
Alexander, G. (223)
Alexopoulos, T. (223)
Alhroob, M. (223)
Allbrooke, B. M. M. (223)
Allport, P. P. (223)
Aloisio, A. (223)
Altheimer, A. (223)
Amako, K. (223)
Amelung, C. (223)
Amoroso, S. (223)
Amram, N. (223)
Anastopoulos, C. (223)
Ancu, L. S. (223)
Andari, N. (223)
Andeen, T. (223)
Anderson, K. J. (223)
Andreazza, A. (223)
Antonelli, M. (223)
Antonov, A. (223)
Aoki, M. (223)
Arabidze, G. (223)
Arai, Y. (223)
Argyropoulos, S. (223)
Arnaez, O. (223)
Arnal, V. (223)
Artoni, G. (223)
Asai, S. (223)
Asquith, L. (223)
Assamagan, K. (223)
Atkinson, M. (223)
Augsten, K. (223)
visa färre...
Lärosäte
Lunds universitet (225)
Kungliga Tekniska Högskolan (184)
Stockholms universitet (8)
Umeå universitet (6)
Uppsala universitet (5)
Karolinska Institutet (5)
visa fler...
Göteborgs universitet (1)
Chalmers tekniska högskola (1)
Högskolan i Halmstad (1)
visa färre...
Språk
Engelska (237)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (226)
Medicin och hälsovetenskap (10)
Teknik (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy